ArticleBlood cancer journal2018
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.
Article in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Detection of minimal residual disease by next generation sequencing in AL amyloidosis.Blood cancer journal · 2021Trial
- Trial
- Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.Blood advances · 2020Trial
- The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis.Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2020Trial
- Early minimal residual disease eradication in light chain amyloidosis generates deeper and faster cardiac response.Clinical and experimental medicine · 2024Article
- Bad players in AL amyloidosis in the current era of treatment.Expert review of hematology · 2023Article
- Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.Journal of cancer research and clinical oncology · 2022Article
- De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment.HemaSphere · 2021Article
- Article
- Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.Blood cancer journal · 2021Article
- Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation.Journal of nephrology · 2021Article
- The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis.Orphanet journal of rare diseases · 2020Review
- Review
- CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.International journal of molecular sciences · 2020Review
- Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.American journal of hematology · 2020Article
- New developments in diagnosis, risk assessment and management in systemic amyloidosis.Blood reviews · 2020Review
- Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2020Article
- Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.PloS one · 2020Article
- Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses.Frontiers in pharmacology · 2020Review
- Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.Blood advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.